Publication | Open Access
Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose
13
Citations
11
References
2021
Year
Unknown Venue
VaccinationVaccine SafetyVaccine DevelopmentSars-cov-2 InfectionVaccine TargetFirst Vaccine DoseImmunologyFirst DoseVaccine TestingStrong Immune ResponseVaccine EfficacySingle Vaccine DoseVaccine HesitancyMedicineSputnik VViral ImmunityEpidemiologyCovid-19
Abstract We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucumán, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses. One-Sentence Summary First vaccine dose in subjects with prior COVID19 elicits a higher antibody response than two doses in uninfected individuals
| Year | Citations | |
|---|---|---|
2020 | 23.1K | |
2021 | 2.6K | |
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, VaccinationVaccine SafetyVaccinologyInterim AnalysisVaccine Development | 2021 | 1.8K |
2020 | 1.4K | |
2020 | 968 | |
2020 | 782 | |
2020 | 702 | |
2020 | 325 | |
2020 | 258 | |
2020 | 206 |
Page 1
Page 1